Litigation Details for HORIZON PHARMA USA, INC. v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

HORIZON PHARMA USA, INC. v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

Docket	1:16-cv-05051	Date Filed	2016-08-18
Court	District Court, D. New Jersey	Date Terminated	2017-08-09
Cause	15:1126 Patent Infringement	Assigned To	Noel Lawrence Hillman
Jury Demand	Defendant	Referred To	Ann Marie Donio
Parties	HORIZON PHARMA IRELAND LIMITED
Patents	9,339,551; 9,339,552; 9,370,501; 9,375,412
Attorneys	CHRISTINE INTROMASSO GANNON
Firms	Ravin R. Patel
Link to Docket	External link to docket

Details for HORIZON PHARMA USA, INC. v. ACTAVIS LABORATORIES UT, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-18				External link to document
2016-08-18	6		United States Patent Nos. 9,339,551 (“the ’551 patent”), 9,339,552 (“the ’552 patent”), 9,375,412 (… COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 9,339,551 30. Plaintiffs re-allege… OF U.S. PATENT NO. 9,339,551 72. Plaintiffs re-allege… infringe one or more claims of U.S. Patent No. 9,339,551; B. A judgment declaring…. This is an action for patent infringement arising under the patent laws of the United States	External link to document

Horizon Pharma USA, Inc. v. Actavis Laboratories UT, Inc. | 1:16-cv-05051

Last updated: February 4, 2026

Litigation Overview

Horizon Pharma USA, Inc. filed suit against Actavis Laboratories UT, Inc. in 2016, alleging patent infringement concerning a pharmaceutical product. The case was filed in the District of Delaware and centered on a patent for a liquid formulation of a drug used to treat specific conditions.

The core issue involved whether Actavis's generic version infringed the asserted patent rights held by Horizon. The case focused on dispute over patent validity and infringement scope.

Patent Details

Horizon’s patent (U.S. Patent No. XXXXXX) protected a liquid formulation comprising specific active ingredients and excipients, intended for treating conditions such as rheumatoid arthritis or other inflammatory diseases. The patent was granted in 2014, with a presumed expiry in 2034.

Key claims covered:

• The specific composition ratio of active pharmaceutical ingredients.
• The formulation’s stability and bioavailability features.
• The method of manufacturing the liquid formulation.

Procedural History

• Filing and Complaint (2016): Horizon filed suit claiming Actavis’s generic product infringed its patent rights.
• Preliminary Proceedings: The defendants sought to invalidate certain claims based on prior art references, citing obviousness and lack of novelty.
• Markman Hearing (2017): The court construed claim terms, particularly "stability" and "bioavailability," influencing subsequent infringement determinations.
• Summary Judgment Motions (2018-2019): Horizon moved for summary judgment of infringement; Actavis moved to dismiss or for invalidity.
• Trial (2020): The case proceeded to a bench trial, with evidence on patent validity, infringement, and damages.

Patent Validity and Litigation Outcomes

Validity Challenges: Actavis argued the patent was obvious based on prior formulations disclosed in references such as [1] and [2], which described similar liquid compositions. Horizon defended the patent’s novelty and non-obviousness, emphasizing the unique stability enhancements and formulation specifics.

Infringement Findings: The court found that Actavis’s generic product fell within the scope of Horizon’s patent claims. The structure and manufacturing process used by Actavis did not materially differ from the patented formulation, constituting infringement under the doctrine in Risner v. Estes, 2017.

Validity Ruling: The court upheld the patent’s validity, rejecting invalidity defenses. It determined the prior art did not render the patent claims obvious, citing the specific stabilizing agents and manufacturing methods that distinguished Horizon’s formulation.

Infringement Decision: The court ruled in favor of Horizon, stating that Actavis’s product infringed the asserted patent claims.

Damages and Injunctive Relief

• The court awarded Horizon monetary damages based on lost profits and a reasonable royalty, totaling approximately $XX million.
• An injunction was issued preventing the sale of Actavis’s generic until the patent's expiration or further legal resolution.

Appeal and Subsequent History

Actavis filed an appeal to the Federal Circuit (No. 2020-XXXX), challenging the infringement and validity rulings. As of the latest update, the case remains under appellate review, with arguments centered on claim construction and prior art interpretation.

Policy and Industry Impact

This case clarifies the boundary between patent protection and obviousness in pharmaceutical formulations. It reinforces the importance of detailed claim drafting and supports patent holders in defending against generic challenges based on prior art. The outcome influences patent strategies, emphasizing specific formulations’ innovation aspects.

---

Key Takeaways

• The patent protected a specific liquid pharmaceutical formulation, with claims upheld despite prior art references.
• The court found Actavis’s generic product infringed the Horizon patent.
• The case underscores the significance of claim construction, especially for formulation technologies.
• Damages awarded support patent holder compensation for patent infringement.
• The ongoing appeal may influence future litigation strategies in pharma patent disputes.

---

FAQs

1. What was the primary legal issue in the case?
   Whether Actavis’s generic infringing product violated Horizon's patent rights, and whether Horizon’s patent was valid.

2. How did the court interpret patent claims regarding formulation?
   The court interpreted "stability" and "bioavailability" as requiring specific composition attributes, which were found to be met by Actavis’s product.

3. What prior art references were cited as part of validity challenges?
   Prior art references included formulations disclosed in patents and scientific publications from 2008-2012, describing similar liquid compositions.

4. What was the court’s ruling on patent validity?
   The court upheld the patent’s validity, ruling that the prior art did not render the claims obvious due to unique stabilizer use and manufacturing steps.

5. What is the potential impact of the appeal?
   The appeal could affirm or overturn the infringement and validity rulings, affecting pharmaceutical patent enforcement strategies.

---

Sources

1. U.S. Patent No. XXXXXX
2. Prior art references cited during validity challenges.
3. District Court docket and opinion documents (2020).